References
- Porter J, Bowden DK, Economou M, et al. Health-related quality of life, treatment satisfaction, adherence and persistence in β-thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox: results from the EPIC Clinical Trial. Anemia. 2012;2012:297641. doi: 10.1155/2012/297641. Epub 2012 Aug 12
- Cappellini MD, Musallam KM, Taher AT. Overview of iron chelation therapy with desferrioxamine and deferiprone. Hemoglobin. 2009;33(Suppl 1):S58–S69
- Hershko CM, Link GM, Konijn AM, Cabantchik ZI. Iron chelation therapy. Curr Hematol Rep. 2005;4(2):110–116
- Giardina PJ, Grady RW. Chelation therapy in β-thalassemia: an optimistic update. Semin Hematol. 2001;38(4):360–366
- Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995;332(14):918–922
- Cohen AR, Galanello R, Piga A, et al. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol. 2000;108(2):305–312
- Beratis S. Psychosocial status in pre-adolescent children with β-thalassaemia. J Psychosom Res. 1993;37(3):271–279
- Caro J, Ward A, Green T, et al. Impact of thalassemia major on patients and their families. Acta Haematol. 2002;107(3):150–157
- Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2(8653):27–30
- Modell B, Khan M, Darlison M. Survival in β-thalassemia major in the UK: data from the UK Thalassemia Register. Lancet. 2000;355(9220):2051–2052
- Brittenham G, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Eng J Med. 1994;331(9):567–573
- Ratip S, Modell B. Psychological and sociological aspects of the thalassemias. Semin Hematol. 1996;33(1):53–65
- Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med. 1994;331(9):574–578
- Zahed L, Mourad FH, Alameddine R, et al. Effect of oral iron chelation therapy with deferiprone (L1) on the psychosocial status of thalassaemia patients. Haematologia (Budap). 2002;31(4):333–339
- Psihogios V, Rodda C, Reid E, et al. Reproductive health in individuals with homozygous β-thalassaemia: knowledge, attitudes and behaviour. Fertil Steril. 2002;77(1):119–127
- Politis C, DiPalma A, Fisfis M, et al. Social integration of the older thalassaemia patient. Arch Dis Child. 1990;65(9):984–986
- Zani B, DiPalma A, Vullo C. Psychological aspects of chronic illness in adolescents with thalassemia major. J Adolesc. 1995;18(2):387–402
- Chan GCF, Ng DMW, Fong DYT, et al. Comparison of subcutaneous infusion needles for transfusion-dependent thalassemia patients by the intrapersonal cross-over assessment model. Am J Hematol. 2004;76(4):398–404
- Olivieri N. Adherence to deferoxamine therapy: heeding Hippocrates and Osler. Am J Hematol. 2004;76(4):415–416
- Pidgeon V. Compliance with chronic illness regimens: school aged children and adolescents. J Pediatr Nurs. 1989;4(1):36–47
- Cromer B, Tarnowski KJ. Non-compliance in adolescents: a review. J Dev Behav Pediatr. 1989;10(4):207–215
- Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann NY Acad Sci. 1998;850:227–231
- Goldbeck L, Baving A, Kohne E. Psychosocial aspects of β-thalassemia: distress, coping and adherence. Klin Padiatr. 2000;212(5):254–259 (in German)
- Trachtenberg F, Vichinsky E, Haines D, et al.; Thalassemia Clinical Research Network. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol. 2011;86(5):433–436
- Goulas V, Kourakli A, Camoutsis C. Comparative effects of three iron chelation therapies on the quality of life of Greek patients with homozygous transfusion-dependent β-thalassemia. ISRN Hematol. 2012;2012:139862. doi: 10.5402/2012/139862. Epub 2012 Dec 17